The connubium among diabetes, chronic kidney disease and atrial fibrillation

Magnocavallo, Michele; Vetta, Giampaolo; Trivigno, Sara; Mariani, Marco Valerio; Lullo, Luca Di; Bellasi, Antonio; Rocca, Domenico Giovanni Della; Severino, Paolo; Piro, Agostino; Giunta, Gaetano; Quaglione, Raffaele; Lavalle, Carlo

doi:10.23736/s2724-5683.22.05891-4

Cited by 4 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the former risk factors also increase the risk of VTE, which represents a leading cause of in-hospital death and requires lifelong anticoagulation if recurrent or without identified risk factors [ 2 ]. Anticoagulation therapy is pivotal in those two conditions: in AF patients, anticoagulation prevents the feared thromboembolic complications, such as ischemic stroke and systemic embolism [ 7 ], while in VTE patients’ anticoagulation clears clots preventing hemodynamic instability due to acute right HF and long-term PE sequelae such as chronic thromboembolic pulmonary hypertension (CTEPH), due to the persistence and organization of thrombi in pulmonary arterial bed [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network

Lavalle

Mariani

Piro

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: Direct oral anticoagulants (DOACs) are the preferred anticoagulant drugs for the prevention of atrial fibrillation (AF)-related thromboembolic complications and for the treatment and the prevention of recurrences of venous thromboembolism (VTE). The evaluation of self-reported adverse drug reactions (ADRs) available from databases of drug-regulatory agencies such as the Italian Medicines Agency (AIFA) pharmacovigilance database represents a novel aid to guide decision making. Objective: To assess the safety profile of DOACs by analyzing ADR rates in the real-world Italian scenario. Methods: Post-marketing surveillance data recorded by the National Pharmacovigilance Network were retrieved for the time period 2017–2021 from the AIFA online site. The following data were collected for each DOAC: total ADR number, serious ADR number, gastrointestinal (GI) ADR, intracranial hemorrhage events (ICH ADR), and more frequently reported ADR for the study year. The safety profile was expressed by the risk index (RI). Results: Rivaroxaban use was associated with consistent and stable low rates of serious ADR, GI ADR, and ICH ADR across the 5-year study period. Rivaroxaban and apixaban showed the lowest RI for serious ADR and GI ADR, while rivaroxaban use was associated with significantly lower ICH events as compared to apixaban. Dabigatran was related to the highest RIs for every ADR class, in particular GI ADRs. Conclusions: DOACs presented an acceptable safety profile in the current post-market analysis. However, rivaroxaban and apixaban were associated with more favorable safety profiles as compared to dabigatran, while rivaroxaban provoked statistically significantly fewer ICH events as compared to apixaban.

show abstract

Section: Introductionmentioning

confidence: 99%